The following are key points to remember from a state-of-the-art review on anthracycline cardiotoxicity in adult cancer patients: ...

Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma In the article accompanying this editorial, Jensen et al 20 provide an update on the READ ...

Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller Access the segment ...

HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a ...

CNS Pharmaceuticals (NASDAQ: CNSP) , focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in ...

For patients with operative triple-negative breast cancer, a multigene signature can help tailor adjuvant chemotherapy, ...

Detailed price information for Cns Pharmaceuticals Inc (CNSP-Q) from The Globe and Mail including charting and trades.

CNS Pharmaceuticals (NASDAQ: CNSP) announced that it received an exception from the nasdaq Hearings Panel, granting the company until March 11, 2025, to meet the minimum bid price requirement under ...

Health experts want blood- and breast-cancer patients prescribed exercise to mitigate heart damage during treatment.

A multigene signature can be used to guide decisions about adjuvant therapy in patients with triple-negative breast cancer, data suggest.